205 related articles for article (PubMed ID: 12432547)
1. In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R-roscovitine).
McClue SJ; Blake D; Clarke R; Cowan A; Cummings L; Fischer PM; MacKenzie M; Melville J; Stewart K; Wang S; Zhelev N; Zheleva D; Lane DP
Int J Cancer; 2002 Dec; 102(5):463-8. PubMed ID: 12432547
[TBL] [Abstract][Full Text] [Related]
2. The Cyclin-dependent kinase inhibitor CYC202 (R-roscovitine) inhibits retinoblastoma protein phosphorylation, causes loss of Cyclin D1, and activates the mitogen-activated protein kinase pathway.
Whittaker SR; Walton MI; Garrett MD; Workman P
Cancer Res; 2004 Jan; 64(1):262-72. PubMed ID: 14729633
[TBL] [Abstract][Full Text] [Related]
3. In vitro and in vivo pharmacokinetic-pharmacodynamic relationships for the trisubstituted aminopurine cyclin-dependent kinase inhibitors olomoucine, bohemine and CYC202.
Raynaud FI; Whittaker SR; Fischer PM; McClue S; Walton MI; Barrie SE; Garrett MD; Rogers P; Clarke SJ; Kelland LR; Valenti M; Brunton L; Eccles S; Lane DP; Workman P
Clin Cancer Res; 2005 Jul; 11(13):4875-87. PubMed ID: 16000586
[TBL] [Abstract][Full Text] [Related]
4. In vitro activity of cyclin-dependent kinase inhibitor CYC202 (Seliciclib, R-roscovitine) in mantle cell lymphomas.
Lacrima K; Valentini A; Lambertini C; Taborelli M; Rinaldi A; Zucca E; Catapano C; Cavalli F; Gianella-Borradori A; Maccallum DE; Bertoni F
Ann Oncol; 2005 Jul; 16(7):1169-76. PubMed ID: 15851403
[TBL] [Abstract][Full Text] [Related]
5. Effects of the cyclin-dependent kinase inhibitor CYC202 (R-roscovitine) on the physiology of cultured human keratinocytes.
Atanasova G; Jans R; Zhelev N; Mitev V; Poumay Y
Biochem Pharmacol; 2005 Sep; 70(6):824-36. PubMed ID: 16011834
[TBL] [Abstract][Full Text] [Related]
6. Cyclin-dependent kinase inhibitor (roscovitine) suppresses growth and induces apoptosis by regulating Bcl-x in head and neck squamous cell carcinoma cells.
Mihara M; Shintani S; Kiyota A; Matsumura T; Wong DT
Int J Oncol; 2002 Jul; 21(1):95-101. PubMed ID: 12063555
[TBL] [Abstract][Full Text] [Related]
7. The cyclin-dependent kinase inhibitors olomoucine and roscovitine arrest human fibroblasts in G1 phase by specific inhibition of CDK2 kinase activity.
Alessi F; Quarta S; Savio M; Riva F; Rossi L; Stivala LA; Scovassi AI; Meijer L; Prosperi E
Exp Cell Res; 1998 Nov; 245(1):8-18. PubMed ID: 9828096
[TBL] [Abstract][Full Text] [Related]
8. Flavopiridol, a novel cyclin-dependent kinase inhibitor, suppresses the growth of head and neck squamous cell carcinomas by inducing apoptosis.
Patel V; Senderowicz AM; Pinto D; Igishi T; Raffeld M; Quintanilla-Martinez L; Ensley JF; Sausville EA; Gutkind JS
J Clin Invest; 1998 Nov; 102(9):1674-81. PubMed ID: 9802881
[TBL] [Abstract][Full Text] [Related]
9. A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days.
Benson C; White J; De Bono J; O'Donnell A; Raynaud F; Cruickshank C; McGrath H; Walton M; Workman P; Kaye S; Cassidy J; Gianella-Borradori A; Judson I; Twelves C
Br J Cancer; 2007 Jan; 96(1):29-37. PubMed ID: 17179992
[TBL] [Abstract][Full Text] [Related]
10. Anti-angiogenic effects of purine inhibitors of cyclin dependent kinases.
Liebl J; Krystof V; Vereb G; Takács L; Strnad M; Pechan P; Havlicek L; Zatloukal M; Fürst R; Vollmar AM; Zahler S
Angiogenesis; 2011 Sep; 14(3):281-91. PubMed ID: 21487803
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis and biological evaluation of 6-pyridylmethylaminopurines as CDK inhibitors.
Wilson SC; Atrash B; Barlow C; Eccles S; Fischer PM; Hayes A; Kelland L; Jackson W; Jarman M; Mirza A; Moreno J; Nutley BP; Raynaud FI; Sheldrake P; Walton M; Westwood R; Whittaker S; Workman P; McDonald E
Bioorg Med Chem; 2011 Nov; 19(22):6949-65. PubMed ID: 21982796
[TBL] [Abstract][Full Text] [Related]
12. Seliciclib in malignancies.
Aldoss IT; Tashi T; Ganti AK
Expert Opin Investig Drugs; 2009 Dec; 18(12):1957-65. PubMed ID: 19938906
[TBL] [Abstract][Full Text] [Related]
13. Seliciclib (CYC202, R-roscovitine) enhances the antitumor effect of doxorubicin in vivo in a breast cancer xenograft model.
Appleyard MV; O'Neill MA; Murray KE; Paulin FE; Bray SE; Kernohan NM; Levison DA; Lane DP; Thompson AM
Int J Cancer; 2009 Jan; 124(2):465-72. PubMed ID: 19003963
[TBL] [Abstract][Full Text] [Related]
14. Antiviral activity of CYC202 in HIV-1-infected cells.
Agbottah E; de La Fuente C; Nekhai S; Barnett A; Gianella-Borradori A; Pumfery A; Kashanchi F
J Biol Chem; 2005 Jan; 280(4):3029-42. PubMed ID: 15531588
[TBL] [Abstract][Full Text] [Related]
15. Cyclin-dependent kinase inhibitor Roscovitine induces apoptosis in chronic lymphocytic leukemia cells.
Hahntow IN; Schneller F; Oelsner M; Weick K; Ringshausen I; Fend F; Peschel C; Decker T
Leukemia; 2004 Apr; 18(4):747-55. PubMed ID: 14973497
[TBL] [Abstract][Full Text] [Related]
16. CR8, a potent and selective, roscovitine-derived inhibitor of cyclin-dependent kinases.
Bettayeb K; Oumata N; Echalier A; Ferandin Y; Endicott JA; Galons H; Meijer L
Oncogene; 2008 Oct; 27(44):5797-807. PubMed ID: 18574471
[TBL] [Abstract][Full Text] [Related]
17. R-roscovitine (CYC202) alleviates renal cell proliferation in nephritis without aggravating podocyte injury.
Milovanceva-Popovska M; Kunter U; Ostendorf T; Petermann A; Rong S; Eitner F; Kerjaschki D; Barnett A; Floege J
Kidney Int; 2005 Apr; 67(4):1362-70. PubMed ID: 15780088
[TBL] [Abstract][Full Text] [Related]
18. Reversal of collapsing glomerulopathy in mice with the cyclin-dependent kinase inhibitor CYC202.
Gherardi D; D'Agati V; Chu TH; Barnett A; Gianella-Borradori A; Gelman IH; Nelson PJ
J Am Soc Nephrol; 2004 May; 15(5):1212-22. PubMed ID: 15100361
[TBL] [Abstract][Full Text] [Related]
19. Expression of pRB, cyclin/cyclin-dependent kinases and E2F1/DP-1 in human tumor lines in cell culture and in xenograft tissues and response to cell cycle agents.
Lu K; Shih C; Teicher BA
Cancer Chemother Pharmacol; 2000; 46(4):293-304. PubMed ID: 11052627
[TBL] [Abstract][Full Text] [Related]
20. Potent induction of wild-type p53-dependent transcription in tumour cells by a synthetic inhibitor of cyclin-dependent kinases.
Kotala V; Uldrijan S; Horky M; Trbusek M; Strnad M; Vojtesek B
Cell Mol Life Sci; 2001 Aug; 58(9):1333-9. PubMed ID: 11577989
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
